Fulgent Genetics Reports Widened Losses, Negative Operating Cash Flow, and Anticipates Significant 2026 Revenue Decline from Key Customer
FLGT sits 50% above its 52-week low of $14.57 on elevated volume (3.0× avg).
Summary
Fulgent Genetics reported increased net losses and a shift to negative operating cash flow in 2025, with a significant revenue decline expected in 2026 due to a major customer insourcing services. The company also faces ongoing legal investigations related to past billing practices.
Key Events · Earnings and Guidance · FLGT
-
Financial Performance Deterioration
Net loss widened to $60.5 million in 2025 from $42.7 million in 2024, an increase of 42%. Operating loss also increased by 23% to $91.1 million.
-
Shift to Negative Operating Cash Flow
The company used $101.6 million in cash from operating activities in 2025, a significant reversal from the $21.1 million generated in 2024, indicating increased cash burn.
-
Significant 2026 Revenue Headwind
Management expects reduced revenues in 2026, especially in the first half, from a single large customer that accounted for 22% ($70.8 million) of total revenue in 2025, as this customer begins performing tests internally.
-
Major Legal and Regulatory Investigations
Fulgent Genetics is subject to ongoing DOJ Civil Investigative Demands (CIDs) related to False Claims Act allegations (medically unnecessary testing, improper billing, Anti-Kickback Statute, Stark Law violations) and an HRSA audit concerning $548.9 million in COVID-19 test reimbursements. A qui tam complaint related to COVID-19 testing was unsealed and dismissed without prejudice in February 2026, but can be refiled.
Analysis · FLGT · Industrial Applications And Services
Fulgent Genetics' annual report reveals a challenging financial landscape with a substantial increase in net loss to $60.5 million in 2025 from $42.7 million in 2024, and a significant shift to negative operating cash flow, using $101.6 million in 2025 compared to generating $21.1 million in 2024. The company projects a material revenue decline in 2026, particularly in the first half, due to a major customer (representing 22% of 2025 revenue) bringing testing services in-house. This financial deterioration is compounded by ongoing DOJ Civil Investigative Demands and an HRSA audit related to past COVID-19 testing reimbursements, posing considerable legal and financial risks. While strategic acquisitions and therapeutic R&D efforts are underway, the immediate financial outlook and regulatory overhang present significant concerns for investors.
How filings like this one have moved
In the 30 days to Sep 20, 2026, 34.7% of the 1039 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, FLGT was trading at $21.90 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $765.4M. The 52-week trading range was $14.57 to $31.04. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.